This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HI 164 OV
Description: HI-164OV is an orally-administered non-typeable Haemophilus influenzae (NTHi) immunotherapeutic treatment for chronic obstructive pulmonary disease (COPD). NTHi can drive a specific T cell response that by promoting intrabronchial phagocytosis downregulates bronchus inflammation.
Deal Structure: HI-164OV was developed using intellectual propoerty originating from the University of Newcastle.
Progen Pharmaceuticalss wholly owned subsidiaryPharmaSynth Pty Ltd assists in the manufacturing of active ingredients for HI-164OV.
Additional information available to subscribers only: